scispace - formally typeset
Open AccessJournal ArticleDOI

The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017

Reads0
Chats0
TLDR
Generally, the burden of AML became heavier during the past 28 years which might need more health resources to resolve this population aging-associated problem.
Abstract
Acute myeloid leukemia (AML) is a common leukemia subtype and has a poor prognosis. The risk of AML is highly related to age. In the context of population aging, a comprehensive report presenting epidemiological trends of AML is evaluable for policy-marker to allocate healthy resources. This study was based on the Global Burden of Disease 2017 database. We analyzed the change trends of incidence rate, death rate, and disability-adjusted life year (DALY) rate by calculating the corresponding estimated annual percentage change (EAPC) values. Besides, we investigated the influence of social development degree on AML’s epidemiological trends and potential risk factors for AML-related mortality. From 1990 to 2017, the incidence of AML gradually increased in the globe. Males and elder people had a higher possibility to develop AML. Developed countries tended to have higher age-standardized incidence rate and death rate than developing regions. Smoking, high body mass index, occupational exposure to benzene, and formaldehyde were the main risk factors for AML-related mortality. Notably, the contribution ratio of exposure to carcinogens was significantly increased in the low social-demographic index (SDI) region than in the high SDI region. Generally, the burden of AML became heavier during the past 28 years which might need more health resources to resolve this population aging-associated problem. In the present stage, developed countries with high SDI had the most AML incidences and deaths. At the same time, developing countries with middle- or low-middle SDI also need to take actions to relieve rapidly increased AML burden.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches:

TL;DR: Advances in immunotherapy employ monoclonal and bispecific antibodies, chimeric antigen receptor (CAR) T cells, checkpoint inhibitors, and vaccines provide an alternative pathway for AML treatment.
Journal ArticleDOI

Cancer biomarkers for targeted therapy

TL;DR: Search for novel biomarkers and new designs as well as delivery methods of targeted agents are fueling the next wave of advances in cancer therapy.
Journal ArticleDOI

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.

TL;DR: It is shown that longer overall survival and higher response rate are associated with gilteritinib in comparison with salvage chemotherapy for relapse /refractory (R/R) AML, and data from the ADMIRAL study may lead to the therapy paradigm shift and establish giltersionib as the new standard therapy for R/R FLT3-mutated AML.
Journal ArticleDOI

Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019.

TL;DR: In this paper, the authors analyzed the mortality and morbidity of 29 types of cancer in 204 countries or regions from 1990 to 2019 to guide global cancer prevention and control, and found that individuals over 50 years had the highest risk of developing cancer with incidences and deaths in this age group accounting for more than 85% of cancers in all age groups.
References
More filters
Journal ArticleDOI

Cancer statistics, 2017

TL;DR: The American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.
Journal ArticleDOI

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

TL;DR: Age-related clonal hematopoiesis is a common condition that is associated with increases in the risk of hematologic cancer and in all-cause mortality, with the latter possibly due to an increased risk of cardiovascular disease.
Related Papers (5)